Enzene Opens Hopewell Facility
Enzene Biosciences, a contract development and manufacturing organization, celebrated the opening of an 80,000 square-foot biologics manufacturing plant in Hopewell in early September, marking the culmination of a U.S. expansion first announced in 2023.
The $50 million facility at the Princeton West Innovation campus is the company’s first manufacturing outpost in the U.S. The ribbon cutting was attended by Governor Phil Murphy as well as First Lady Tammy Murphy, Hopewell Township Mayor Courtney Peters-Manning, and delegates from the offices of Senator Andy Kim and Congresswoman Bonnie Watson Coleman.
“When Enzene — one of India’s most promising biotechnological companies — decided to launch its very first U.S. manufacturing base, they knew there was nowhere better to do it than right here in New Jersey. Their decision reflects not only our state’s strength as a hub for global business and innovation, but also the deep cultural ties that bind New Jersey and India,” said Governor Phil Murphy. “This state-of-the-art facility represents the future of advanced manufacturing — ultimately creating hundreds of jobs and generating $50 million in investment. As Enzene expands its presence here in New Jersey, we remain committed to supporting the company as it builds the world-class manufacturing ecosystem of tomorrow.”
“We are proud to bring our global expertise to the U.S. and contribute to the advancement of biopharmaceutical manufacturing,” said Himanshu Gadgil, CEO of Enzene. “Our first-to-market manufacturing technology is forging a new path in biologics manufacturing that will provide a cost-efficient, high yield, U.S.-based biomanufacturing solution for biopharmaceutical innovators, and complement our facilities in India to provide global supply solutions.”
More information: www.enzene.com.
Biocon Ltd. Adds Cranbury Facility
Biocon Limited, a global biopharmaceutical company, has announced the inauguration of its first U.S. manufacturing facility in Cranbury, by its wholly owned subsidiary, Biocon Generics Inc (BGI).
“We are incredibly grateful that Biocon has decided to open its first U.S. manufacturing facility in the Garden State,” said Governor Phil Murphy, the guest of honor at the inauguration. “This state-of-the-art facility marks a significant moment in Biocon’s global expansion and reinforces New Jersey’s reputation as the medicine chest to the world.”
Biocon acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested more than $30 million to establish a state-of-the-art plant with an annual production capacity of 2 billion tablets. A few products have already been commercialized from the site, with several more in the pipeline. This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint.
The Cranbury facility represents a strategic advancement for the company’s U.S. operations, enabling faster access to essential therapies, enhanced supply reliability and a stronger connection with partners and healthcare providers, ultimately benefitting patients across the United States.
OneWell Health Opens Princeton Headquarters
OneWell Health has relocated its New Jersey headquarters to Princeton and announced a new leadership team for its New Jersey presence.
The company, which offers services for individuals with intellectual and developmental disabilities, currently operates in California, Colorado, Connecticut, Georgia, Massachusetts, Pennsylvania, South Carolina, and New Jersey. The specific location of its new Princeton headquarters was not disclosed.
The new leadership team includes Brandon Cherry, who is tasked with overseeing OneWell’s expansion of services and partnerships within the state; Taylor Hirocheck, in charge of hands-on leadership, quality service, and community presence at the local level; and Morgan Davis, leading OneWell’s New Jersey team in harmony with broader company strategy.
More information: www.onewell.org.
